Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Orfit Industries
New Application in Radiation Oncology to Enable Enhanced Patient Comfort, Treatment Precision, Environmental Benefits
JERICHO, N.Y., Jan. 21, 2014 /PRNewswire/ -- Orfit Industries America, North American subsidiary of Orfit Industries, a world leader in patient immobilization systems, today announced that it has received FDA clearance to market its Nanor™ hybrid thermoplastic technology for use in an immobilization mask for radiation therapy. The Company estimates that immobilization products using the advanced technology will become available for sale in the United States during the first half of 2014.
Orfit's advanced nano-technology will be used in the Company's new Nanor™ masks, creating a mask that is 33 to 50 percent thinner than conventional masks. These masks exhibit much less shrinkage and are light yet stable, ultimately increasing patient comfort. Since the mask better conforms to a patient's head, it provides higher stability during radiation therapy. The nano technology-enhanced masks are also better for the environment, as they use less material and create less waste.
About Orfit Industries
A family-owned business headquartered in Antwerp, Belgium, Orfit Industries is a market leader in the development and manufacturing of low temperature thermoplastics, hardware and accessories for patient immobilization and positioning in radiation oncology. With exports to more than 80 countries worldwide, the company also manufactures thermoplastic materials for the physical rehabilitation and technical orthopedics markets, such as splints and prostheses. In addition to Orfit Industries America, its North American subsidiary based in Jericho, New York, Orfit has subsidiaries in Germany and France.
Follow Orfit online
©2012 PR Newswire. All Rights Reserved.